
|Articles|October 1, 2001
Combination therapy may be answer for CTCL
Anaheim, Calif. - Combination therapy with biological responsemodifiers and careful and regular reassessment of refractory patients areof paramount importance in the effective treatment of cutaneous T-cell lymphoma,according to Carmela C. Vittorio, M.D.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Next-Generation IL-4Rα Targeting and Potential Dermatologic Implications
2
Recludix Pharma’s REX-8756 for Type 2 Inflammatory Diseases Enters First Human Trials
3
Alpha Tau Submits First PMA Module to FDA for Novel cSCC Treatment, Alpha DaRT
4
Oruka Reports Positive Interim Phase 1 Data for ORKA-002, Advances ORKA-001
5


















